Wandercraft in the news

Three French tech companies, Mistral, Wandercraft, and The Exploration Company, are expected to announce major fundraising rounds this September, with Mistral eyeing 3 billion euros, Wandercraft 100 million euros, and The Exploration Company 300 million dollars.

Wandercraft is raising €100M at a €750M valuation as Renault plans to deploy 350 of its humanoid robots in factories by 2027.

Wandercraft, a robotics startup backed by Renault, is in talks to raise €100 million to fund its expansion into industrial humanoid robots, with Renault planning to deploy 350 of its Calvin robots by 2027.

Wandercraft is reportedly looking to raise 100 million euros with Goldman Sachs, aiming for a 750 million euro valuation to expand its robotics and exoskeleton business.

Wandercraft secured 12 customers for its Calvin-40 industrial humanoid robot, aiming for market dominance by expanding capabilities and scaling production through strategic partnerships.

Wandercraft is launching its self-balancing Eve exoskeleton in the U.S. for wheelchair users, enabling hands-free mobility and expanding into the personal medical equipment market.

Wandercraft, driven by a personal family story, develops exoskeletons for rehabilitation and daily use, and is expanding into industrial humanoid robotics with partnerships and significant funding.

Wandercraft obtained FDA clearance for its Eve exoskeleton, enabling upright mobility for wheelchair users, with a U.S. launch set for September 2026.

Good Shepherd Rehabilitation partners with Wandercraft to bring a new personal exoskeleton, Eve, to market, enhancing mobility for individuals with severe disabilities.

Wandercraft's self-balancing exoskeleton, Eve, secured FDA clearance for upright mobility in wheelchair users with spinal cord injuries.

Wandercraft's Eve, a self-balancing walking exoskeleton, has received FDA clearance for personal use by adults with spinal cord injuries, with a U.S. commercial launch planned for September 2026.

Wandercraft is moving its headquarters to a new location in Paris's 13th arrondissement, seeking a larger and more suitable space for its expanding operations.

Renault is integrating Wandercraft's Calvin humanoid robots into its factories for demanding tasks, with plans for widespread deployment by 2027.

Wandercraft's co-founder explains the global robotics competition and the impact of autonomous exoskeleton technology on society.

Renault and Wandercraft are partnering to deploy hundreds of autonomous humanoid robots for heavy lifting and manual tasks on automotive assembly lines.

Wandercraft develops robotic exoskeletons that help paralyzed patients walk and improve their physical health during rehabilitation sessions.

A new humanoid robot launch and rising exoskeleton market demand present growth opportunities despite French economic budget concerns.

Wandercraft initiated a clinical pilot at Brigham and Women’s Hospital to evaluate using the Atalante X self-balancing exoskeleton for early mobilization of thoracic surgery patients in the ICU.

Clinical trials at Brigham and Women’s Hospital are testing whether self-balancing exoskeletons can safely mobilize ICU patients faster while reducing staff labor requirements.

Autonomous robotic exoskeletons enable paraplegic patients to stand and walk hands-free using motorized leg technology.